-
Grazoprevir hydrate: HCV Assay Workflows
2026-09-14
Build genotype-aware HCV replication assays around a potent NS3/4A protease inhibitor, from DMSO stock preparation through orthogonal validation. Practical protocol parameters, controls, and troubleshooting guidance help distinguish true antiviral activity from cytotoxicity, dosing error, or resistance-related assay drift.
-
Podophyllotoxin Workflows for Cell-Cycle Studies
2026-09-14
Build reproducible assays around Podophyllotoxin’s microtubule-directed disruption, then separate mitotic arrest from apoptosis and autophagy responses with orthogonal controls. The workflow also translates a hepatocellular carcinoma study of the distinct compound JXE-23 into practical assay-design choices without conflating the two molecules.
-
Human iPSC Intestinal Organoids for Pharmacokinetic Studies
2026-09-13
Saito and colleagues developed a direct three-dimensional cluster culture strategy for generating expandable, cryopreservable intestinal organoids from human induced pluripotent stem cells. The resulting organoid-derived epithelial cells contain mature intestinal populations and show cytochrome P450 and transporter activities, supporting more human-relevant pharmacokinetic studies than conventional models alone.
-
Valemetostat in Relapsed/Refractory Non-Hodgkin Lymphoma
2026-09-12
This first-in-human phase 1 study evaluated Valemetostat, also known as DS-3201, as an oral dual EZH2/EZH1 inhibitor in relapsed or refractory non-Hodgkin lymphoma. The trial established a recommended phase 2 dose of 200 mg daily and showed a 54.5% overall response rate in the efficacy population, while defining cytopenias and infection risk as important safety considerations.
-
L-Threonine Workflows for Metabolic Profiling
2026-09-11
Use L-Threonine as a controlled nutrient variable for cell culture optimization, metabolic profiling, and nutritional intervention studies—not as a direct ALP inhibitor. Pairing nutrient-controlled biology with a metal-free carbon-dot nanozyme assay creates a practical workflow for separating metabolic effects from analytical interference.
-
Entecavir BA1816 for Reliable HBV Assays
2026-09-11
This scenario-based guide explains how Entecavir (SKU BA1816) can improve experimental reasoning in HBV replication, viability, proliferation, and cytotoxicity workflows. It covers assay interpretation, solvent compatibility, protocol controls, resistance comparisons, and evidence-based product selection.
-
Light-Controlled RNA Release for Regulated Gene Therapy
2026-09-10
The reference study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that controls therapeutic protein production at the translational level. In mouse models, LIRP-regulated AAV systems enabled ambient-light activation of therapeutic genes and reversible interruption of retinal VEGF inhibition, providing a compact optogenetic framework for more adaptable gene therapies.
-
FH1 Small Molecule for Mature iHep Models
2026-09-10
FH1 small molecule supports a more functional hepatocyte-like cell platform by improving albumin secretion, CYP3A4 levels, colony morphology, and AFP-related maturity readouts. This practical guide connects FH1 handling and assay design with emerging light-regulated gene-control research while clearly separating validated product findings from forward-looking applications.
-
Relative and Fractional Viability in Cancer Assays
2026-09-09
Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that these metrics capture different combinations of growth inhibition and cell death. The framework improves interpretation of in vitro anticancer responses by aligning endpoint selection with the biological question and by emphasizing response timing.
-
AZD8055: Practical mTOR Inhibitor Workflow
2026-09-09
AZD8055 (SKU A8214) provides a selective ATP-competitive approach for studying mTORC1 and mTORC2 signaling in biochemical and cellular workflows. This guide covers solvent handling, assay controls, pathway verification, and interpretation limits; it is not a clinical efficacy protocol and is unsuitable for water-based formulation without independent validation.
-
AL-8810: Precision FP Receptor Antagonism
2026-09-08
AL-8810 is a selective prostaglandin F2α antagonist for dissecting PTGFR signaling in vascular, smooth muscle, ocular, and endometrial models. This guide translates recent menstrual-like model findings into practical assay strategies centered on receptor-level pharmacology, pathway validation, and orthogonal functional readouts.
-
Phosphatase Inhibitor Cocktail 1: Evidence Guide
2026-09-08
Phosphatase Inhibitor Cocktail 1 is a 100X DMSO-based alkaline phosphatase inhibitor formulation for preserving protein phosphorylation during sample preparation. Its composition supports phosphoproteomic analysis and phospho-signaling assays, but the cited liver-stress study provides biological context rather than direct validation of this reagent.
-
Silymarin: From Flavonolignan Chemistry to Translation
2026-09-07
Silymarin is more than a botanical antioxidant: it is a chemically complex flavonolignan reference material whose value depends on composition-aware assay design, orthogonal validation, and disciplined translational interpretation.
-
In Vitro Activity of Midecamycin: 1983 Findings
2026-09-07
Harold C. Neu’s 1983 study established a comparative in vitro profile for midecamycin, an acetoxy-substituted macrolide antibiotic, across clinically derived Gram-positive and Gram-negative isolates. The work showed useful activity against many streptococci, staphylococci, Haemophilus influenzae, and Listeria, but substantially weaker performance than erythromycin and no meaningful activity against erythromycin-resistant isolates or most tested Enterobacteriaceae and Pseudomonas.
-
Salinomycin Workflow for HCC Research
2026-09-05
Build a reproducible Salinomycin workflow for hepatocellular carcinoma research by combining viability, apoptosis, calcium, transporter, and Wnt/β-catenin readouts. The approach separates practical assay optimization from ionophore-toxicity considerations, helping researchers distinguish pathway-specific effects from nonspecific membrane or vehicle stress.